natgillin/translations-raw huggingface dataset:
Undesirable effects possibly related to filgrastim therapy and typically occurring in &lt; 2% of SCN patients were injection site reaction, headache, hepatomegaly, arthralgia, alopecia, osteoporosis, and rash.
Nuspojave koje mogu biti povezane s terapijom filgrastimom i koje su se u pravilu pojavile u &lt; 2 % bolesnika s teškom kroničnom neutropenijom bile su reakcija na mjestu injekcije, glavobolja, hepatomegalija, artralgija, alopecija, osteoporoza i osip.
Undesirable effects possibly related to filgrastim therapy and typically occurring in &lt; 2% of SCN patients were injection site reaction, headache, hepatomegaly, arthralgia, alopecia, osteoporosis, and rash.
Nuspojave za koje postoji moguća povezanost s liječenjem filgrastimom i koje su se obično pojavile u &lt; 2% bolesnika s teškom kroničnom neutropenijom bile su reakcija na mjestu primjene, glavobolja, hepatomegalija, artralgija, alopecija, osteoporoza i osip.
Undesirable effects possibly related to filgrastim therapy and typically occurring in &lt; 2% of SCN patients were injection site reaction, headache, hepatomegaly, arthralgia, alopecia, osteoporosis, and rash.
Nuspojave za koje postoji moguća povezanost s liječenjemfilgrastimom i koje su se obično pojavile u &lt; 2% bolesnika s teškom kroničnom neutropenijom bile su reakcija na mjestu primjene, glavobolja, hepatomegalija, artralgija, alopecija, osteoporoza i osip.
Unexplained motor neuropathy, muscle weakness, or sensory neuropathy lasting &gt; 4 days must be evaluated, and non-inflammatory causes such as disease progression, infections, metabolic syndromes and concomitant medication should be excluded.
Neobjašnjiva motorička neuropatija, mišićna slabost ili senzorička neuropatija koje traju &gt; 4 dana moraju se ispitati i moraju se isključiti neupalni uzroci poput napredovanja bolesti, infekcije, metaboličkog sindroma i istodobno primijenjenih lijekova.
Unless otherwise prescribed, the recommended posology in adults aged &gt; 21 years is 2000 U/m2 every 14 days.
Osim ako nije drugačije propisano, preporučeno doziranje u odraslih osoba u dobi ˃ 21 godine iznosi 2000 U/m2 svakih 14 dana.
Until more is known about the implications of these findings the use of riociguat in children and in growing adolescents should be avoided (see section &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; &lt; 4.4).
Dok se ne sazna više o značenju ovih nalaza potrebno je izbjegavati primjenu riocigvata u djece i adolescenata koji rastu (vidjeti dio 4.4).
Up to 20, 37 and 20 metabolites were detected in plasma, urine and faeces respectively, the majority of them representing &lt; 1% of the dosed material.
U plazmi, mokraći odnosno fecesu pronađeno je čak do 20, 37 odnosno 20 metabolita, a većina njih činila je &lt; 1% primijenjene doze.
Upon initiation of treatment, a reversible increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and an absolute count &gt; 5,000/mcL), often associated with reduction of lymphadenopathy, has been observed in about three fourths of patients with CLL treated with IMBRUVICA.
Po uvođenju liječenja kod otprilike tri četvrtine bolesnika s KLL-om liječenih lijekom IMBRUVICA bio je uočen reverzibilan porast broja limfocita (tj. ≥ 50% porast u odnosu na početnu vrijednost i apsolutni broj &gt; 5000/μl), često udružen sa smanjenjem limfadenopatije.
Uric acid levels were &lt; 2 mg/dl in 96% of patients in the two arms containing rasburicase and 5% of patients in the allopurinol arm at 4 hours of the day 1 dose.
Četiri sata nakon primjene doze prvog dana liječenja razine mokraćne kiseline bile su &lt; 2 mg/dl u 96% bolesnika u dvije skupine koje su primale razburikazu i u 5% bolesnika u skupini koja je primala alopurinol.
Urinary protein positive ( &gt; 1+)
Mokraća pozitivna na proteine ( &gt; 1+) 
Use a 10 ml oral dosing syringe for administration of volumes ≤10 ml or a 20 ml oral dosing syringe for administration of volumes &gt; 10 ml.
Za primjenu volumena ≤10 ml uporabite oralnu štrcaljku za doziranje od 10 ml, a za primjenu volumena &gt; 10 ml uporabite oralnu štrcaljku za doziranje od 20 ml.
Use in adolescents (Age 15- &lt; 18)
Primjena u adolescenata (dob od 15 do &lt; 18)
Use in children (including neonates) &lt; 4 months
Primjena u djece (uključujući novorođenčad) u dobi ˂ 4 mjeseca
Use in children (including neonates) &lt; 4 months of age
Primjena u djece (uključujući novorođenčad) u dobi &lt; 4 mjeseca
Use in children &gt; 4 months of age and adolescents &lt; 16 years of age
Primjena u djece u dobi od 4 mjeseca ili više i adolescenata mlađih od 16 godina
Use in children and newborns &lt; 4 months of age
Primjena u djece i novorođenčadi mlađe od 4 mjeseca
Use in children under &lt; 3 years is not recommended due to insufficient experience in this age group.
Primjena u djece u dobi od &lt; 3 godine se ne preporučuje zbog nedostatnog iskustva u ovoj dobnoj skupini.
Use in children ≥ 4 months of age up to adolescents &lt; 16 years of age
Primjena u djece u dobi od ≥ 4 mjeseca do adolescenata u dobi &lt; 16 godina
Use in children ≥ 4 months of age up to adolescents &lt; 16 years of age
Primjena u djece u dobi od ≥ 4 mjeseca do adolescenata u dobi ˂ 16 godina
Use in elderly ( &gt; 75 years)
Primjena u starijih osoba ( &gt; 75 godina)
Use in paediatric patients aged 2 to &lt; 12 years with hepatic or renal insufficiency has not been studied (see sections 4.8 and 5.2).
Nije se ispitivala primjena u pedijatrijskih bolesnika u dobi od 2 do &lt; 12 godina s oštećenjem jetre ili bubrega (vidjeti dijelove 4.8 i 5.2).
Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).
U bolesnika s klirensom kreatinina &lt; 15 ml/mm ne preporučuje se primjena lijeka (vidjeti dijelove 4.2 i 5.2).
Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).
Upotreba se ne preporučuje u bolesnika s klirensom kreatinina &lt; 15 ml/min (vidjeti dijelove 4.2 i 5.2).
Use is not recommended in patients with creatinine clearance &lt; 15 ml/min.
Ne preporučuje se primjena lijeka Xarelto u bolesnika s klirensom kreatinina &lt; 15 ml/min.
Use of 2 ml presentations has not been documented for paediatric subjects &lt; 2 years of age.
Primjena oblika od 2 ml nije dokumentirana u djeci mlađoj od 2 godine.
Use of Lojuxta is contraindicated in patients treated with high doses of simvastatin ( &gt; 40 mg) (see sections 4.3 and 4.4).
Primjena Lojuxte kontraindicirana je u bolesnika liječenih visokim dozama simvastatina ( &gt; 40 mg) (vidjeti dijelove 4.3 i 4.4).
Using a global improvement scale (PGI), significantly more women using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p &lt; 0.001).
Prema ljestvici ukupnog poboljšanja (PGI) značajno veći broj žena liječenih duloksetinom nego onih koje su primale placebo smatralo je da im je liječenje ublažilo njihove simptome (64,6% naspram 50,1%, p &lt; 0,001).
Using a noncompleter/switch = failure analysis, 50% (21/42) of subjects receiving tenofovir disoproxil fumarate, 76% (28/37) of subjects receiving emtricitabine plus tenofovir disoproxil fumarate and 52% (11/21) of subjects receiving entecavir achieved HBV DNA &lt; 400 copies/ml at week 168.
Analiza podataka o ispitanicima koji nisu dovršili ispitivanje/promjeni terapije = neuspjeh, pokazala je da su 50% (21/42) ispitanika koji su primali tenofovirdizoproksilfumarat, 76% (28/37) ispitanika koji su primali emtricitabin i tenofovirdizoproksilfumarat i 52% (11/21) ispitanika koji su primali entekavir postigli HBV DNK &lt; 400 kopija/ml u 168. tjednu.
Using a sensitive immunoassay &lt; 1% of patients treated with denosumab for up to 3 years tested positive for non neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.
Korištenjem osjetljivog imunotesta, &lt; 1% bolesnika liječenih denosumabom u trajanju do 3 godine bilo je pozitivno na neneutralizirajuća vezujuća protutijela bez dokaza o promjeni u farmakokinetici, toksičnosti ili kliničkom odgovoru.
Using a sensitive immunoassay &lt; 1% of patients treated with denosumab for up to 5 years tested positive for non neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.
Korištenjem osjetljive metode „imunoassay” &lt; 1% bolesnika koji se primali denosumab u razdoblju do 5 godina bilo je pozitivno na ne-neutralizirajuća vezna protutijela, bez dokaza o izmijenjenoj farmakokinetici, toksičnosti ili kliničkom odgovoru.
Using an ITT analysis, the overall proportions of patients with HIV RNA &lt; 400 copies/mL and
Primjenom ITT analize, ukupan udio bolesnika s HIV RNK &lt; 400 kopija/ml i &lt; 50 kopija/ml u
Using an ITT analysis, the overall proportions of patients with HIV RNA &lt; 400 copies/mL and &lt; 50 copies/mL at Week 48 were 57% (21/37) and 46% (17/37), respectively.
Primjenom ITT analize, ukupan udio bolesnika s HIV RNK &lt; 400 kopija/ml i &lt; 50 kopija/ml u 48. tjednu bio je 57% (21/37), odnosno 46% (17/37).
Uusaru 5
PAVLIDES &amp; ARAOUZOS LTD
V87P11 Elderly ( &gt; 60 years) N=142
V87P11 Starije osobe ( &gt; 60 godina)
Vaccination should be postponed during any illness with fever &gt; 38.5°C.
Cijepljenje se mora odgoditi za vrijeme trajanja bilo koje bolesti s vrućicom &gt; 38,5°C.
Vaccination should be postponed during any illness with fever &gt; 38.5C.
Cijepljenje se mora odgoditi za vrijeme trajanja bilo koje bolesti s vrućicom &gt; 38,5C.
Vaccine efficacy results in children &gt; 36 months of age suggest a waning of protection.
Rezultati djelotvornosti cjepiva u djece u dobi &gt; 36 mjeseci ukazuju na slabljenje zaštite.
Valsartan shows multiexponential decay kinetics (t½α &lt; 1 h and t½ß about 9 h).
Valsartan pokazuje multieksponencijalnu kinetiku raspadanja (t½α &lt; 1 h i t½ß oko 9 h).
Varenicline is highly selective and binds more potently to the α4β2 receptor subtype (Ki=0.15 nM) than to other common nicotinic receptors (α3β4 Ki=84 nM, α7 Ki= 620 nM, α1βγδ Ki= 3,400 nM), or to non-nicotinic receptors and transporters (Ki &gt; 1µM, except to 5-HT3 receptors: Ki=350 nM).
Vareniklin je visoko selektivan i jače se veže za receptorski podtip α4β2 (Ki=0,15 nM) nego za ostale uobičajene nikotinske receptore (α3β4 Ki=84 nM, α7 Ki= 620 nM, α1βγδ Ki= 3400 nM), odnosno nenikotinske receptore i prijenosnike (Ki &gt; 1µM, osim za 5-HT3 receptore: Ki=350 nM).
Varenicline pharmacokinetics were unchanged in subjects with mild renal impairment (estimated creatinine clearance &gt; 50 ml/min and  80 ml/min).
Farmakokinetika vareniklina ostala je neizmijenjena u ispitanika s blagim oštećenjem bubrežne funkcije (procijenjeni klirens kreatinina &gt; 50 ml/min i ≤ 80 ml/min).
Variants V36A/M, T54A/S, R155K/T, and A156S conferred lower levels of in vitro resistance to telaprevir (3- to 25-fold increase in telaprevir IC50), and the A156V/T and V36M+R155K variants conferred higher levels of in vitro resistance to telaprevir ( &gt; 25-fold increase in telaprevir IC50).
Varijante V36A/M, T54A/S, R155K/T i A156S pokazale su in vitro nižu razinu rezistencije na telaprevir (povećanje IC50 telaprevira za 3 do 25 puta), dok su varijante A156V/T i V36M+R155K in vitro pokazale više razine rezistencije na telaprevir (povećanje IC50 telaprevira za &gt; 25 puta).
Vectra 3D for dogs &gt; 40 kg
Vectra 3D za pse teže od 40 kg
Vectra 3D for dogs &gt; 40 kg
Vectra 3D za pse težine &gt; 40 kg
Vectra 3D spot-on (1.5–4 kg) Vectra 3D spot-on (4–10 kg) Vectra 3D spot-on (10–25 kg) Vectra 3D spot-on (25–40 kg) Vectra 3D spot-on ( &gt; 40 kg)
Vectra 3D za nakapavanje (1,5 – 4 kg) Vectra 3D za nakapavanje (4 – 10 kg) Vectra 3D za nakapavanje (10 – 25 kg) Vectra 3D za nakapavanje (25 – 40 kg) Vectra 3D za nakapavanje ( &gt; 40 kg)
Vectra 3D spot-on solution for dogs 1.5–4 kg Vectra 3D spot-on solution for dogs 4–10 kg Vectra 3D spot-on solution for dogs 10–25 kg Vectra 3D spot-on solution for dogs 25–40 kg Vectra 3D spot-on solution for dogs &gt; 40 kg
Vectra 3D otopina za nakapavanje za pse 1,5 – 4 kg Vectra 3D otopina za nakapavanje za pse 4 – 10 kg Vectra 3D otopina za nakapavanje za pse 10 – 25 kg Vectra 3D otopina za nakapavanje za pse 25 – 40 kg Vectra 3D otopina za nakapavanje za pse teže od 40 kg
VELCADE therapy should be withheld when the platelet count is &lt; 25,000/l or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/l (see section 4.2).
Liječenje VELCADEom mora se prekinuti kad je broj trombocita &lt; 25 000/l, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/l (vidjeti dio 4.2).
Velmetia should not be used in patients with moderate or severe renal impairment (creatinine clearance &lt; 60 mL/min) (see sections 4.3 and 4.4).
Velmetia se ne smije primjenjivati u bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 60 ml/min) (vidjeti dijelove 4.3 i 4.4).
Velpatasvir is &gt; 99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09 μg/mL to 1.8 μg/mL.
Velpatasvir je &gt; 99,5 % vezan za proteine ljudske plazme i vezanje ne ovisi o koncentraciji lijeka u rasponu od 0,09 μg/ml do 1,8 μg/ml.
very common ( &gt; 1/10)
vrlo često (1/10)
very common ( &gt; 1/10), common ( &gt; 1/100 to &lt; 1/10), uncommon ( &gt; 1/1000 to &lt; 1/100), rare ( &gt; 1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
vrlo često ( &gt; 1/10), često ( &gt; 1/100 i &lt; 1/10), manje često ( &gt; 1/1000 i &lt; 1/100), rijetko ( &gt; 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
very common ( &gt; 1/10): hypotension, heart rate and rhythm disorders, angina pectoris
vrlo često ( &gt; 1/10): hipotenzija, poremećaji srčane frekvencije i ritma, angina pektoris
Very common (≥ 1/10) Common (≥ 1/100 to &lt; 1/10)
vrlo često (≥ 1/10)
Very Common (≥ 1/10) Common (≥ 1/100 to &lt; 1/10)
Vrlo često (≥ 1/10) Često (≥ 1/100 i &lt; 1/10)
Very common (≥ 1/10); Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥ 1/10,000 to &lt; 1/1,000); Very rare ( &lt; 1/10,000), not known (cannot be estimated from available data).
Vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne mogu se procijeniti iz raspoloživih podataka).
Very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (nije moguće procijeniti iz dostupnih podataka).
Very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10000), nepoznato (nije moguće procijeniti iz dostupnih podataka).
Very common (≥ 1/10); Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥ 1/10,000 to &lt; 1/1,000); Very rare ( &lt; 1/10,000).
Vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
Very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare( &lt; 1/10,000), not known (cannot be estimated from the available data).
Vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (nije moguće procijeniti iz dostupnih podataka).
Very common (≥ 1/10); Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥1/10,000 to &lt; 1/1,000); Very rare ( &lt; 1/10,000).
Vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
Very common (≥ 1/10); Common (≥ 1/100 to  1/10); Uncommon (≥ 1/1,000 to &lt; 1/100);
Vrlo često (≥ 1/10), često (≥ 1/100 i  1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i
Very common (≥ 1/10); Common (≥ 1/100, &lt; 1/10); Uncommon (≥ 1/1,000, &lt; 1/100)
MedDRAklasifikaciji organskih sustava i MedDRA izrazu vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100)
Very common (≥ 1/10); Common (≥ 1/100, &lt; 1/10); Uncommon (≥ 1/1,000, &lt; 1/100)
Vrlo često (≥ 1/10); Često (≥ 1/100, &lt; 1/10); Manje često (≥ 1/1000, &lt; 1/100)
Very common (≥1/10 patient-years); Common (≥1/100 to &lt; 1/10 patient-years);
često (≥1/100 i &lt; 1/10 bolesnik-godina);
Very common (≥1/10)
Često (≥1/100 i &lt; 1/10)
Very common (≥1/10) Common (≥1/100 and &lt; 1/10)
vrlo često (≥ 1/10) često (≥ 1/100 i &lt; 1/10)
Very common (≥1/10) Common (≥1/100 to &lt; 1/10)
Vrlo često (≥1/10) Često (≥1/100 i &lt; 1/10)
Very common (≥1/10) Common (≥1/100 to &lt; 1/10)
Vrlo često (≥1/10) Često (≥1/100 do &lt; 1/10)
Very common (≥1/10), Common (≥1/100 to &lt; 1/10), Uncommon (≥1/1,000 to &lt; 1/100), Rare (≥1/10,000 to
Vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i
Very common (≥1/10); Common (≥1/100 to &lt; 1/10); Uncommon (≥1/1,000 to &lt; 1/100);
Vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do
Very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Very common (≥1/10); Common (≥1/100, &lt; 1/10); Uncommon (≥1/1,000, &lt; 1/100); Rare (≥1/10,000,
Vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i
Very common ( 1/10) Common ( 1/100 to &lt; 1/10)
vrlo često (≥ 1/10) često (≥ 1/100 i &lt; 1/10) manje često (≥ 1/1000 i &lt; 1/100)
Very common (1/10) Common (1/100 to &lt; 1/10)
Vrlo često (1/10) Često (1/100 i &lt; 1/10)
Very common &gt; 1/10 Common 1/100 to &lt; 1/10
Vrlo često &gt; 1/10
Very common &gt; 1/10 Common 1/100 to &lt; 1/10
vrlo često &gt; 1/10 često  1/100 i &lt; 1/10
Very common symptoms in overdose ( &gt; 10 % incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10 %) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10 %) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija &gt; 10%) uključuju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidne simptome i smanjenu razinu svijesti u rasponu od sedacije do kome.
Very common symptoms in overdose ( &gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (prisutni u &gt; 10% slučajeva) uključuju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidne simptome i smanjenje razine svijesti u rasponu od sedacije do kome.
Very common ≥ 1/10 Common ≥ 1/100 to &lt; 1/10
vrlo često ≥ 1/10
Very common: (≥ 1/10) Common: (≥1/100 to &lt; 1/10)
Vrlo često: (≥ 1/10)
Very common: (≥1/10) Common: (≥1/100 to &lt; 1/10)
Vrlo često: ( 1/10)
Very common: ≥ 1/10;
Vrlo često: ≥ 1/10; Često: ≥ 1/100 do &lt; 1/10;
Very common: ≥1/10; common: ≥1/100 to &lt; 1/10; uncommon: ≥1/1,000 to &lt; 1/100; rare: ≥1/10,000 to
Vrlo često: ≥1/10; često: ≥1/100 i &lt; 1/10; manje često: ≥1/1000 i &lt; 1/100; rijetko: ≥1/10 000 i
Very common: 1/10 Common: 1/100 to &lt; 1/10
Vrlo često: ≥1/10
Very limited data are available in patients &gt; 75 years of age.
Vrlo je malo podataka za bolesnike starije od 75 godina.
Very limited data in seronegative subjects &gt; 80 years of age (N=5) showed that no subject achieved seroprotection rate following two administrations of a single dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1).
Vrlo ograničeni podaci u seronegativnih ispitanika &gt; 80 godina (N=5) pokazali su da nitko od ispitanika nije postigao stopu seroprotekcije nakon dvije primjene jednostruke doze AS03- adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina iz soja A/Vietnam/1194/2004 (H5N1).
very premature infants ( &lt; 28 weeks gestational age and/or body weight &lt; 1000 g) particularly when receiving parenteral nutrition
vrlo nezrela nedonoščad (gestacijske dobi &lt; 28 tjedna i/ili tjelesne težine &lt; 1000 g) osobito kad primaju parenteralnu prehranu
Very rare ( &lt; 1/10,000)
Vrlo rijetko ( &lt; 1/10 000)
Very rare ( &lt; 1/10,000)
Vrlo rijetko ( &lt; 1/10 000